Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Events
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Washington Life Science Industry Directory

EquipNet Auction: Looking to sell your pre-owned equipment? Sell it Now!

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Alder BioPharmaceuticals, Inc.


Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South
Bothell, WA 98011
Alder BioPharmaceuticals, Inc.
 
Phone: (425) 205-2900
Fax: (425) 205-2901
Year Established:  2004
Employees: 59
Ticker: ALDR
Exchange: NASDAQ
Main Contact: Mark Litton, Ph.D., CBO & Treasurer
 
Other Contacts:  Eric Carter, Ph.D., M.D., Interim CMO
Erin Lavelle, COO
Elisabeth A. Sandoval, CCO
Annette Vahratian, Senior VP, Quality
Randy Hassler, Senior VP, Pharmaceutical Operations
James B. Bucher, J.D., Senior VP & General Counsel
Larry Benedict, Executive VP & Principal Accounting Officer
Paul B. Cleveland, Interim President & CEO
Jeffrey T.L. Smith, M.D., FRCP, Senior VP, Translational Medicine
John A. Latham, Ph.D., CSO
 
Company Description
Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, Alder's clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.